BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 7975491)

  • 1. Kill and cure. The hope and reality of virus inactivation.
    Prowse C
    Vox Sang; 1994; 67 Suppl 3():191-6. PubMed ID: 7975491
    [No Abstract]   [Full Text] [Related]  

  • 2. Virus inactivation of fresh plasma.
    Mohr H
    Vox Sang; 1998; 74 Suppl 2():171-2. PubMed ID: 9704442
    [No Abstract]   [Full Text] [Related]  

  • 3. [Virus in hemophilia: current status and future perspectives].
    Aguilar C; Félix Lucía J
    Sangre (Barc); 1996 Apr; 41(2):141-5. PubMed ID: 9045355
    [No Abstract]   [Full Text] [Related]  

  • 4. Approaches to the reduction of viral infectivity in cellular blood components and single donor plasma.
    Wagner SJ; Friedman LI; Dodd RY
    Transfus Med Rev; 1991 Jan; 5(1):18-32. PubMed ID: 1802274
    [No Abstract]   [Full Text] [Related]  

  • 5. Photodynamic virus inactivation of blood components.
    Mohr H; Lambrecht B; Selz A
    Immunol Invest; 1995; 24(1-2):73-85. PubMed ID: 7713607
    [No Abstract]   [Full Text] [Related]  

  • 6. [Viral safety considerations in immunoglobulin preparations].
    Gómez Manzano P; Escrivá CA; Salmerón García F; Alonso Verduras C
    Sangre (Barc); 1997 Jun; 42(3):199-203. PubMed ID: 9381262
    [No Abstract]   [Full Text] [Related]  

  • 7. Inactivation of viruses in blood and plasma products.
    Suomela H
    Transfus Med Rev; 1993 Jan; 7(1):42-57. PubMed ID: 8431658
    [No Abstract]   [Full Text] [Related]  

  • 8. Reducing the residual risk of transfusion-transmitted viruses: mini-pool or single-donation NAT?
    Roth WK; Seifried E
    Transfusion; 2001 Jun; 41(6):845-7. PubMed ID: 11399831
    [No Abstract]   [Full Text] [Related]  

  • 9. [Evaluation of viral safety of a high-purity human factor VIII concentrate submitted to 2 specific virus inactivation treatments (FANDHI)].
    Ristol P; Gensana M; Fernández J; Massot M; Biescas H; Darling A; Jorquera JI; Vericat F
    Sangre (Barc); 1996 Apr; 41(2):131-6. PubMed ID: 9045353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful clinical use of a plasma-derived, dual virus inactivated factor VII concentrate incorporating solvent-detergent and dry heat treatment.
    Smith MP; Rice KM; Savidge GF
    Thromb Haemost; 1997 Feb; 77(2):406-7. PubMed ID: 9157608
    [No Abstract]   [Full Text] [Related]  

  • 11. [Viral safety measures of plasma for transfusion and applicability in Spain].
    Pereira A
    Med Clin (Barc); 2007 Oct; 129(12):458-68. PubMed ID: 17953912
    [No Abstract]   [Full Text] [Related]  

  • 12. Genomic screening for blood-borne viruses in transfusion settings.
    Lee HH; Allain JP
    Vox Sang; 1998; 74 Suppl 2():119-23. PubMed ID: 9704433
    [No Abstract]   [Full Text] [Related]  

  • 13. Strategies for reducing the exposure to donor blood.
    Murphy M
    Clin Med (Lond); 2005; 5(4):337-40. PubMed ID: 16138487
    [No Abstract]   [Full Text] [Related]  

  • 14. Inactivation of viruses found with plasma proteins.
    Horowitz B
    Biotechnology; 1991; 19():417-30. PubMed ID: 1786476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virus inactivation in blood components by photoactive phenothiazine dyes.
    Wagner SJ
    Transfus Med Rev; 2002 Jan; 16(1):61-6. PubMed ID: 11788930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virus validation experiments on the production process of OCTAVI SDPlus.
    Biesert L; Lemon S; Suhartono H; Wang L; Rübsamen H
    Blood Coagul Fibrinolysis; 1995 Jul; 6 Suppl 2():S48-54. PubMed ID: 7495968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A solvent I detergent treated, pasteurised and highly purified factor VIII concentrate.
    Schwinn H; Stadler M; Josic D; Bal F; Gehringer W; Nur I; Schütz R
    Arzneimittelforschung; 1994 Feb; 44(2):188-91. PubMed ID: 8147954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Photoinactivation of viruses and cells for medical applications.
    Corash L; Hanson CV
    Blood Cells; 1992; 18(1):3-5. PubMed ID: 1617191
    [No Abstract]   [Full Text] [Related]  

  • 19. [Viral safety of hemoderivatives: in search of zero risk].
    Hernández JM; Tusell JM
    Sangre (Barc); 1996 Apr; 41(2):97-100. PubMed ID: 9045365
    [No Abstract]   [Full Text] [Related]  

  • 20. The role of leukodepletion in the control of transfusion-transmitted disease.
    Goldman M; Delage G
    Transfus Med Rev; 1995 Jan; 9(1):9-19. PubMed ID: 7719040
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.